Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Subscribe To Our Newsletter & Stay Updated